JP2019513384A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513384A5
JP2019513384A5 JP2018553128A JP2018553128A JP2019513384A5 JP 2019513384 A5 JP2019513384 A5 JP 2019513384A5 JP 2018553128 A JP2018553128 A JP 2018553128A JP 2018553128 A JP2018553128 A JP 2018553128A JP 2019513384 A5 JP2019513384 A5 JP 2019513384A5
Authority
JP
Japan
Prior art keywords
rna complex
antisense strand
bonds
sense strand
strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553128A
Other languages
English (en)
Japanese (ja)
Other versions
JP7049262B2 (ja
JP2019513384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000470 external-priority patent/WO2017178883A2/en
Publication of JP2019513384A publication Critical patent/JP2019513384A/ja
Publication of JP2019513384A5 publication Critical patent/JP2019513384A5/ja
Application granted granted Critical
Publication of JP7049262B2 publication Critical patent/JP7049262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553128A 2016-04-11 2017-04-10 結合組織成長因子を標的とするrna複合体を用いた特発性肺胞線維症の治療 Active JP7049262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320944P 2016-04-11 2016-04-11
US62/320,944 2016-04-11
PCT/IB2017/000470 WO2017178883A2 (en) 2016-04-11 2017-04-10 Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor

Publications (3)

Publication Number Publication Date
JP2019513384A JP2019513384A (ja) 2019-05-30
JP2019513384A5 true JP2019513384A5 (enExample) 2020-05-21
JP7049262B2 JP7049262B2 (ja) 2022-04-06

Family

ID=60037955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553128A Active JP7049262B2 (ja) 2016-04-11 2017-04-10 結合組織成長因子を標的とするrna複合体を用いた特発性肺胞線維症の治療

Country Status (7)

Country Link
US (2) US10301628B2 (enExample)
EP (1) EP3443093A4 (enExample)
JP (1) JP7049262B2 (enExample)
KR (1) KR102339886B1 (enExample)
CN (1) CN109072238B (enExample)
CA (1) CA3020487C (enExample)
WO (1) WO2017178883A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2631291B1 (en) 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
DK2853597T3 (en) * 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ,インコーポレーテッド IL4Rα、TRPA1、またはF2RL1を標的とするRNA複合体を用いたアトピー性皮膚炎および喘息の治療
EP3411481A4 (en) 2016-02-02 2020-02-26 Olix Pharmaceuticals, Inc. TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS USING ANGPT2 AND PDGFB TARGETED RNA COMPLEXES
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE
CN112512532B (zh) 2018-07-31 2024-11-08 雷莫内克斯生物制药有限公司 用于抑制ctgf表达的组合物
WO2020027640A1 (ko) * 2018-07-31 2020-02-06 주식회사 레모넥스 Ctgf 발현 억제용 조성물
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
WO2020122534A1 (ko) * 2018-12-10 2020-06-18 올릭스 주식회사 Snai1의 발현을 억제하는 비대칭 sirna
KR102161041B1 (ko) 2018-12-13 2020-10-05 영남대학교 산학협력단 살리노마이신을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN111378655B (zh) * 2018-12-28 2024-03-19 苏州瑞博生物技术股份有限公司 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
AU2020450890B2 (en) * 2020-05-26 2025-04-10 Olix Pharmaceuticals, Inc. RNAi agent targeting MyD88 and use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
US20080188430A1 (en) 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20040248835A1 (en) 2001-10-26 2004-12-09 Anja Krebs Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
US20040138163A1 (en) 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
US20060069050A1 (en) 2004-02-17 2006-03-30 University Of Massachusetts Methods and compositions for mediating gene silencing
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20090170794A1 (en) 2004-09-10 2009-07-02 Somagenics Inc. Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
AU2006235364A1 (en) 2005-04-08 2006-10-19 Marina Biotech, Inc. RNAi therapeutic for respiratory virus infection
WO2006125977A2 (en) 2005-05-25 2006-11-30 The University Of York Hybrid interfering rna
BRPI0611581B1 (pt) 2005-06-24 2021-08-03 Intervet International B.V. Flavivírus quimérico inativado, composição imunogênica, e, vacina
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
CA2638906A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
US20070218495A1 (en) 2006-03-16 2007-09-20 Dharmacon, Inc. Methods, libraries and computer program products for gene silencing with reduced off-target effects
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008109377A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008150897A2 (en) 2007-05-31 2008-12-11 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
US20090004668A1 (en) 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
WO2009020344A2 (en) 2007-08-06 2009-02-12 Postech Acad Ind Found Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
EP2193140B1 (en) 2007-08-27 2016-11-02 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
CN101849008A (zh) 2007-09-19 2010-09-29 应用生物系统有限公司 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
CN103898110A (zh) 2007-10-03 2014-07-02 夸克制药公司 新siRNA结构
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
KR100949791B1 (ko) 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 RNAi 기구를 포화시키지않는 신규한 siRNA 구조 및 그 용도
JP2011518116A (ja) 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体3拮抗薬としての超小型rna
EP2318528A1 (en) 2008-07-24 2011-05-11 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
WO2010026660A1 (ja) 2008-09-08 2010-03-11 学校法人福岡大学 Zfat遺伝子発現抑制rna
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US20100227920A1 (en) 2008-09-29 2010-09-09 The Regents Of The University Of California Aldehyde dehydrogenase inhibitors as novel depigmenting agents
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP2012517815A (ja) 2009-02-18 2012-08-09 サイレンス・セラピューティクス・アーゲー Ang2の発現を阻害するための手段
JP2012520683A (ja) * 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
KR101207561B1 (ko) 2009-12-15 2012-12-04 주식회사 코리아나화장품 티로시나제의 발현을 저해하는 siRNA 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
BR112012024049A2 (pt) * 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
US20130115613A1 (en) 2010-05-12 2013-05-09 Val-Chum, Limited Partnership Screening assays based on mag and/or abhd6 for selecting insulin secretion promoting agent
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
EP2631291B1 (en) 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
US20130324591A1 (en) 2010-12-06 2013-12-05 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
CN102719432B (zh) 2011-03-29 2013-10-23 南京大学 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
KR101590586B1 (ko) 2011-05-30 2016-02-01 성균관대학교산학협력단 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 rna
JP5696991B2 (ja) * 2011-10-28 2015-04-08 国立大学法人三重大学 ヒトTGFβ1を発現するトランスジェニックマウス
DK2853597T3 (en) * 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
US9611473B2 (en) 2012-09-12 2017-04-04 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
EP3591053A1 (en) * 2013-07-05 2020-01-08 Bioneer Corporation Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
KR102279110B1 (ko) * 2014-04-30 2021-07-20 올릭스 주식회사 LasiRNA를 유효성분으로 포함하는 피부 미백용 조성물
WO2015171641A1 (en) 2014-05-05 2015-11-12 Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
CA3022872C (en) 2015-07-27 2024-01-09 Olix Pharmaceuticals, Inc. Rna complexes that inhibit melanin production
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ,インコーポレーテッド IL4Rα、TRPA1、またはF2RL1を標的とするRNA複合体を用いたアトピー性皮膚炎および喘息の治療
EP3411481A4 (en) 2016-02-02 2020-02-26 Olix Pharmaceuticals, Inc. TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS USING ANGPT2 AND PDGFB TARGETED RNA COMPLEXES
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE

Similar Documents

Publication Publication Date Title
JP6924744B2 (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
JP7049262B2 (ja) 結合組織成長因子を標的とするrna複合体を用いた特発性肺胞線維症の治療
TWI495473B (zh) 反義抗病毒化合物及治療流感病毒感染的方法
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
JP6944942B2 (ja) IL4Rα、TRPA1、またはF2RL1を標的とするRNA複合体を用いたアトピー性皮膚炎および喘息の治療
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2019503199A5 (enExample)
JP2016531570A (ja) ユークロマチン領域を標的とするオリゴヌクレオチド
WO2015023939A1 (en) Compositions and methods for modulating expression of frataxin
JP2015523855A (ja) Apoa1及びabca1発現を調節するための組成物及び方法
JP2023519246A5 (enExample)
JP2023536999A (ja) B型肝炎患者のオリゴヌクレオチド処置
WO2023116607A9 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2018533956A5 (enExample)
WO2016134146A2 (en) Rna interference therapeutics against ebola virus
CN108210510A (zh) 一种小干扰核酸药物组合物及其用途
WO2021107143A1 (ja) アンチセンス核酸の毒性を軽減する方法
TWI924663B (zh) 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
WO2026026592A1 (zh) 抑制MAPT基因表达的siRNA及其缀合物和应用
CN116478997A (zh) 用于抑制FGL1的siRNA及其修饰物与应用
CN121003688A (zh) 一种dsRNA与干扰素的联合治疗
US20030216334A1 (en) Methods for inhibiting/treating hiv infections and aids related symptoms
HK40026540A (en) Methods and compositions for inhibiting expression of ldha
WO2001049297A1 (en) Methods for inhibiting/treating hiv infections and aids related symptoms